Edinburgh Napier University

  Nrf2 activators show pre-clinical promise in the treatment of several neurodegenerative diseases, including Alzheimer’s disease (AD), but exert clinical toxicity. Nrf2 regulates hundreds of anti-oxidant response element (ARE)-containing genes, but their specific roles in mediating the onset and progression of neurodegeneration remains unknown. Using human neuron models, this project aims to uncover the molecular mediators which are essential to Nrf2 neuroprotection in AD, with the aim of identifying new drug targets to harness its protective effects whilst limiting off-target toxicity.